CTNM
Contineum Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.44
+5.08%Next report
Analyst consensus
- Next report date
- Oct 29, 2026
- EPS estimate
- -$0.45
- Revenue estimate
- $5.7M
Latest reported
- Last report date
- Jul 30, 2026
- EPS actual
- -$0.40
- EPS estimate
- -$0.45
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 3
- EPS misses (12Q)
- 5
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +9.1%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $21
- PT range
- $14 – $30
- Analysts
- 4
2 Buy2 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Jul 30, 2026 | -$0.45 | -$0.40 | Beat 10.87% | — |
| May 5, 2026 | -$0.55 | -$0.39 | Beat 29.09% | — |
| Mar 5, 2026 | -$0.39 | -$0.49 | Miss -26.03% | — |
| Oct 30, 2025 | -$0.58 | -$0.45 | Beat 22.41% | — |
| May 14, 2025 | -$0.56 | -$0.62 | Miss -10.71% | — |
| Mar 6, 2025 | -$0.44 | -$0.56 | Miss -27.27% | — |
| Aug 13, 2024 | -$0.35 | -$0.39 | Miss -11.43% | — |
| May 16, 2024 | -$0.46 | -$3.55 | Miss -671.74% | — |
| Dec 30, 2023 | — | -$0.31 | — | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Oct 29, 2026